RCUS (Arcus Biosciences) Insider Ownership: 2.99 % (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RCUS Arcus Biosciences Inc RCUS
49 GF Score
Price $28.82
GF Value $7.27
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Arcus Biosciences Insider Ownership?

Arcus Biosciences RCUS +0.35% 49 Insider Ownership is 2.99 % as of Aug. 11, 2026. GuruFocus rates RCUS with a GF Score™ of 49/100 and a GF Value™ of $7.27 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arcus Biosciences's insider ownership is 2.99%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arcus Biosciences's Institutional Ownership is 94.64%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arcus Biosciences's Float Percentage Of Total Shares Outstanding is 61.26%.

Arcus Biosciences Insider Ownership Historical Data

* Premium members only.

The historical data trend for Arcus Biosciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcus Biosciences Insider Ownership Chart

Arcus Biosciences Historical Data

The historical data trend for Arcus Biosciences can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 3.78 3.78 3.78 3.70 3.28 3.07 2.98 2.96 2.99 2.99
RCUS
49GF Score
Arcus Biosciences Inc RCUS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcus Biosciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 2.99 % mean?
Arcus Biosciences (RCUS) has a Insider Ownership of 2.99 % as of Aug. 11, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Arcus Biosciences and its competitors.
Is Arcus Biosciences' Insider Ownership too high?
Arcus Biosciences' current Insider Ownership is 2.99 %. Overall, Arcus Biosciences has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Insider Ownership compare to ALMS and DNLI?
Arcus Biosciences' Insider Ownership of 2.99 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Arcus Biosciences and its competitors. Arcus Biosciences's current Insider Ownership is 2.99 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.27, compared to a current price of $28.82 — trading 296.4% above its estimated fair value. The current Insider Ownership is 2.99 %. Arcus Biosciences' overall GF Score™ is 49/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Insider Ownership is 2.99 % as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $28.82 is trading 296.4% above its estimated GF Value™ of $7.27. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Insider Ownership: 2.99 %
  • GF Value™: $7.27 vs. price of $28.82 (296.4% above fair value)
  • GF Score™: 49/100 with 8 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
49GF Score

Get the complete analysis for RCUS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.82
Price
$7.27
GF Value